Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher

Showing results (361-370 of 6,826) with videos related to

Pageof 683
Sort By:
Nature Reviews. Drug Discovery|April 21, 2021
Long COVID's long R&D agendaAsher Mullard
Nature Reviews. Drug Discovery|June 18, 2026
Multispecific T-cell engagers attract cancer drug developersAsher Mullard
Nature Reviews. Drug Discovery|June 27, 2024
When chronic and rare disease worlds convergeAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
Ipsen buys Epizyme for US$247 millionAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
What should go into a booster shot for COVID-19?Asher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approvalAsher Mullard
Nature Reviews. Drug Discovery|March 5, 2020
N-of-1 drugs push biopharma frontiersAsher Mullard
Nature Reviews. Drug Discovery|August 14, 2023
Chemoproteomic trailblazer advances covalent candidate into the clinic, pushes allosteric agendaAsher Mullard
Nature Reviews. Drug Discovery|June 15, 2021
New hope for anti-obesity drugsAsher Mullard
Nature Reviews. Drug Discovery|October 6, 2020
Mikael DolstenAsher Mullard
Pageof 683

Showing results (361-370 of 6,826) with videos related to

Sort By:
Pageof 683
Nature Reviews. Drug Discovery|April 21, 2021
Long COVID's long R&D agendaAsher Mullard
Nature Reviews. Drug Discovery|June 18, 2026
Multispecific T-cell engagers attract cancer drug developersAsher Mullard
Nature Reviews. Drug Discovery|June 27, 2024
When chronic and rare disease worlds convergeAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
Ipsen buys Epizyme for US$247 millionAsher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
What should go into a booster shot for COVID-19?Asher Mullard
Nature Reviews. Drug Discovery|July 6, 2022
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approvalAsher Mullard
Nature Reviews. Drug Discovery|March 5, 2020
N-of-1 drugs push biopharma frontiersAsher Mullard
Nature Reviews. Drug Discovery|August 14, 2023
Chemoproteomic trailblazer advances covalent candidate into the clinic, pushes allosteric agendaAsher Mullard
Nature Reviews. Drug Discovery|June 15, 2021
New hope for anti-obesity drugsAsher Mullard
Nature Reviews. Drug Discovery|October 6, 2020
Mikael DolstenAsher Mullard
Pageof 683